TLR3 and disease arising from reactivation of latent virus: Our proposal is to enhance trained immunity with dendritic cell adjuvants such as the TLR3 agonist ARNAX to lower the antigen threshold for detecting latent infection and cancer and facilitate the creation of more sensitive and effective preventive vaccines.